Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:21:12.881Z.
Consensus retrieved: 2026-10-06T10:07:01.078Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:21:12.881Z.
Quote observation: 2026-10-06T14:20:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 412370d08cb3fb7a3c2e4d636897a8ea9259835d42853a062d33098765049a4f
FORWARD PE RATIO
N/A
Canopy Growth Corporation
Market Cap
$370.95M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Canopy Growth Corporation (CGC) | $370.95M | N/A |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $376.63M | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $380.98M | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $355.71M | 36.14 |
| Opus Genetics, Inc. (IRD)vs › | $352.14M | N/A |
| Embecta Corp. (EMBC)vs › | $350.92M | 3.36 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $350.69M | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $396.22M | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $341.87M | N/A |
| Agenus Inc. (AGEN)vs › | $340.84M | 30.60 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-03-31
Consensus estimates for this stock are reported in CAD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
